Tumor Budding in Gynecologic Cancer As a Marker for Poor Survival: A Systematic Review and Meta-Analysis of the Perspectives of Epithelial-Mesenchymal Transition

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Mar 25

PMID 35326582

Authors

Muhammad Joan Ailia

Nishant Thakur

Yosep Chong

Kwangil Yim

Affiliations

Soon will be listed here.

Abstract

This study aimed to assess the prognostic significance, assessment methods, and molecular features of tumor budding (TB). A literature search of Medline, EMBASE, Cochrane Library, and eleven cohort studies (seven cervical and four endometrial cancers) was conducted. Three assessment methods for TB involving 2009 patients were collected and constituted in the analysis. Our meta-analysis showed that TB was a marker of poor survival, regardless of the cancer origin site or assessment method (overall survival: hazard ratio [HR], 2.40; 95% confidence interval [CI], 1.82-3.17; disease-free survival: HR, 3.32; 95% CI, 2.46-4.48). In endometrial cancers, TB is associated with the epithelial-mesenchymal transition, microvessel density, and decreased hormone receptor expression. Thus, we suggest TB as a poor prognostic marker for all gynecologic cancers.

Citing Articles

Relationship of Desmoplastic Reaction and Tumour Budding in Primary and Lung Metastatic Lesions of Colorectal Cancer and Their Prognostic Significance.

Kobayashi T, Ishida M, Matsui H, Uehara H, I S, Yamada N Cancers (Basel). 2025; 17(4).

PMID: 40002175 PMC: 11852406. DOI: 10.3390/cancers17040583.

Serous Ovarian Carcinoma: Detailed Analysis of Clinico-Pathological Characteristics as Prognostic Factors.

Aboelnasr L, Meehan H, Saso S, Yague E, El-Bahrawy M Cancers (Basel). 2024; 16(21).

PMID: 39518051 PMC: 11545192. DOI: 10.3390/cancers16213611.

Predictors of Local Invasion in Infiltrative Basal Cell Carcinoma: Tumour Budding Outperforms the WHO Subtyping.

Fernandez-Figueras M, Perez-Munoz N, Puig L, Posada-Caez R, Ballester Victoria R, Henriquez M Acta Derm Venereol. 2024; 104:adv40172.

PMID: 38956962 PMC: 11247513. DOI: 10.2340/actadv.v104.40172.

New Tumor Budding Evaluation in Head and Neck Squamous Cell Carcinomas.

Cacchi C, Fischer H, Wermker K, Rashad A, Jonigk D, Holzle F Cancers (Basel). 2024; 16(3).

PMID: 38339338 PMC: 10854693. DOI: 10.3390/cancers16030587.

Two Cases of Lymph Node Metastasis Found in Differentiated, Small-Sized Gastric Adenocarcinomas: Did Tumor Budding Play a Critical Role?.

Lee Y, Chong Y, Seo K, Yim K Medicina (Kaunas). 2023; 59(12).

PMID: 38138228 PMC: 10745076. DOI: 10.3390/medicina59122126.

References

Zhu Y, Liu H, Xie N, Liu X, Huang H, Wang C . Impact of tumor budding in head and neck squamous cell carcinoma: A meta-analysis. Head Neck. 2018; 41(2):542-550. DOI: 10.1002/hed.25462. View

Jesinghaus M, Strehl J, Boxberg M, Bruhl F, Wenzel A, Konukiewitz B . Introducing a novel highly prognostic grading scheme based on tumour budding and cell nest size for squamous cell carcinoma of the uterine cervix. J Pathol Clin Res. 2018; 4(2):93-102. PMC: 5903696. DOI: 10.1002/cjp2.95. View

Kazama S, Watanabe T, Ajioka Y, Kanazawa T, Nagawa H . Tumour budding at the deepest invasive margin correlates with lymph node metastasis in submucosal colorectal cancer detected by anticytokeratin antibody CAM5.2. Br J Cancer. 2006; 94(2):293-8. PMC: 2361114. DOI: 10.1038/sj.bjc.6602927. View

Guo Y, Zhang Z, Zhao G, Zhao E . Prognostic and pathological impact of tumor budding in gastric cancer: A systematic review and meta-analysis. World J Gastrointest Oncol. 2019; 11(10):898-908. PMC: 6815922. DOI: 10.4251/wjgo.v11.i10.898. View

Koyuncuoglu M, Okyay E, Saatli B, Olgan S, Akin M, Saygili U . Tumor budding and E-Cadherin expression in endometrial carcinoma: are they prognostic factors in endometrial cancer?. Gynecol Oncol. 2011; 125(1):208-13. DOI: 10.1016/j.ygyno.2011.12.433. View

van der Horst P, Wang Y, Vandenput I, Kuhne L, Ewing P, van IJcken W . Progesterone inhibits epithelial-to-mesenchymal transition in endometrial cancer. PLoS One. 2012; 7(1):e30840. PMC: 3266274. DOI: 10.1371/journal.pone.0030840. View

Grigore A, Jolly M, Jia D, Farach-Carson M, Levine H . Tumor Budding: The Name is EMT. Partial EMT. J Clin Med. 2016; 5(5). PMC: 4882480. DOI: 10.3390/jcm5050051. View

Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G, Dawson H . Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017; 30(9):1299-1311. DOI: 10.1038/modpathol.2017.46. View

Wei J, Zhang W, Feng L, Gao W . Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia: A meta-analysis and systematic review. Medicine (Baltimore). 2017; 96(37):e8034. PMC: 5604661. DOI: 10.1097/MD.0000000000008034. View

10.

Kluz T, Lozinski T, Czekierdowska S, Stachowicz N, Gurynowicz G, Chrosciel M . Tumor budding index and microvessel density assessment in patients with endometrial cancer: A pilot study. Oncol Lett. 2020; 20(3):2701-2710. PMC: 7399929. DOI: 10.3892/ol.2020.11811. View

11.

Yamaguchi Y, Ishii G, Kojima M, Yoh K, Otsuka H, Otaki Y . Histopathologic features of the tumor budding in adenocarcinoma of the lung: tumor budding as an index to predict the potential aggressiveness. J Thorac Oncol. 2010; 5(9):1361-8. DOI: 10.1097/JTO.0b013e3181eaf2f3. View

12.

Mazurek A, Kuc P . [Angiogenesis-prognostic factor in patients with endometrial cancer]. Ginekol Pol. 2006; 76(10):838-45. View

13.

Lin L, Zamuco R, Shukla P . Intratumoral budding is associated with poor clinical outcome in early-stage clear cell carcinoma of ovary. Histopathology. 2021; 79(6):1018-1029. DOI: 10.1111/his.14459. View

14.

Satabongkoch N, Khunamornpong S, Pongsuvareeyakul T, Settakorn J, Sukpan K, Soongkhaw A . Prognostic Value of Tumor Budding in Early-Stage Cervical Adenocarcinomas. Asian Pac J Cancer Prev. 2017; 18(6):1717-1722. PMC: 6373798. DOI: 10.22034/APJCP.2017.18.6.1717. View

15.

van Wyk H, Park J, Roxburgh C, Horgan P, Foulis A, McMillan D . The role of tumour budding in predicting survival in patients with primary operable colorectal cancer: a systematic review. Cancer Treat Rev. 2015; 41(2):151-9. DOI: 10.1016/j.ctrv.2014.12.007. View

16.

Lloyd A, Ryan E, Boland M, Elwahab S, Malone C, Sweeney K . The histopathological and molecular features of breast carcinoma with tumour budding-a systematic review and meta-analysis. Breast Cancer Res Treat. 2020; 183(3):503-514. DOI: 10.1007/s10549-020-05810-3. View

17.

Maj E, Papiernik D, Wietrzyk J . Antiangiogenic cancer treatment: The great discovery and greater complexity (Review). Int J Oncol. 2016; 49(5):1773-1784. PMC: 5063425. DOI: 10.3892/ijo.2016.3709. View

18.

Lugli A, Zlobec I, Berger M, Kirsch R, Nagtegaal I . Tumour budding in solid cancers. Nat Rev Clin Oncol. 2020; 18(2):101-115. DOI: 10.1038/s41571-020-0422-y. View

19.

Wang C, Huang H, Huang Z, Wang A, Chen X, Huang L . Tumor budding correlates with poor prognosis and epithelial-mesenchymal transition in tongue squamous cell carcinoma. J Oral Pathol Med. 2011; 40(7):545-51. PMC: 3135705. DOI: 10.1111/j.1600-0714.2011.01041.x. View

20.

Huang B, Cai J, Xu X, Guo S, Wang Z . High-Grade Tumor Budding Stratifies Early-Stage Cervical Cancer with Recurrence Risk. PLoS One. 2016; 11(11):e0166311. PMC: 5115730. DOI: 10.1371/journal.pone.0166311. View